Skip to main content

Table 3 Total budget impact analysis in millions of euros from 2020 to 2040 of Souvenaid from 2020 to 2035 being the health service the payer for diagnosis and dementia medical costs, the Family and Social Services for direct social costs, and the patient for treatment

From: Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain

Year

Control group

Intervention group

Mild dementia

Moderate dementia

Total

Treatment

Diagnosis

Mild dementia

Moderate dementia

Total

2020

7.65

0.23

7.88

5.40

1.36

5.11

0.17

12.05

2021

30.95

1.48

32.43

10.04

1.39

21.17

1.58

34.19

2022

66.25

4.27

70.51

13.94

1.41

46.50

4.68

66.53

2023

111.35

9.83

121.18

17.08

1.44

79.57

10.22

108.31

2024

157.13

19.91

177.04

19.66

1.46

115.86

19.16

156.14

2025

199.76

36.42

236.19

21.89

1.49

151.67

30.70

205.75

2026

235.88

54.74

290.62

23.83

1.52

183.44

45.34

254.13

2027

265.30

72.82

338.12

25.70

1.55

209.78

59.78

296.80

2028

289.59

86.95

376.54

27.46

1.58

231.81

72.64

333.48

2029

306.48

100.24

406.72

29.24

1.61

248.92

84.24

364.01

2030

323.55

110.91

434.46

30.93

1.65

264.50

93.72

390.80

2031

339.18

119.72

458.90

32.52

1.69

280.65

102.65

417.51

2032

352.70

126.32

479.01

34.24

1.72

292.41

110.15

438.52

2033

363.47

134.05

497.53

35.99

1.76

302.46

118.65

458.86

2034

372.31

140.99

513.30

37.66

1.80

313.45

124.84

477.75

2035

384.33

146.61

530.94

39.36

1.84

324.58

131.95

497.73

2036

386.61

152.01

538.61

33.53

-

327.49

138.99

500.00

2037

364.71

154.60

519.31

28.64

-

314.10

144.11

486.86

2038

326.06

153.13

479.19

24.98

-

286.85

144.89

456.72

2039

276.20

148.60

424.80

22.22

-

250.40

142.38

415.00

2040

223.63

137.33

360.96

20.18

-

209.72

135.13

365.03